FDA decision: Iberdomide by BMS/Celgene (in 2026)

Prediction markets aggregate real-money bets from traders with skin in the game, often reflecting forward-looking consensus faster than traditional analyst reports. This market embeds the collective judgment of participants who profit or lose based on accuracy. Analyst forecasts, by contrast, rely on published research and expert opinion but may lag market-driven updates. Comparing this market's odds to published analyst estimates on Iberdomide's regulatory pathway can reveal where the crowd sees asymmetric risk or opportunity relative to institutional research.

On Kalshi, this market is priced through an order-book mechanism where traders directly buy and sell shares representing yes or no outcomes. On Kalshi, prices reflect that venue's order book, liquidity, and how traders price the outcome right now. The price of each share reflects the market's implied probability: a share trading at $0.72 implies a 72% chance of approval. Liquidity and trading volume drive price discovery, so wider spreads may appear during low-activity periods. Your entry and exit prices depend on the live order book, making real-time monitoring essential for optimal execution.

This market resolves around Jan 1, 2027, with the outcome confirmed once the event is verifiable from credible public reporting. The resolution hinges on whether Celgene receives an FDA approval decision for Iberdomide by the end of 2026. Traders holding yes shares profit if approval is granted; those holding no shares profit if it is denied or the deadline passes without approval. The exact resolution will be determined by official FDA announcements and regulatory filings.

Clinical trial data releases, FDA meeting announcements, and regulatory feedback letters are key catalysts that could shift odds significantly. Positive efficacy or safety data typically strengthens approval odds, while adverse events or clinical setbacks weaken them. Competitive approvals in the same therapeutic class may also influence trader sentiment. Additionally, changes in FDA policy, priority review designations, or public health priorities could reshape the regulatory timeline. Monitoring Celgene's investor calls, FDA meeting minutes, and industry news will help you anticipate major moves in this market.